| Code | CSB-RA847747MB1HU |
| Size | |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to AGEN-1571, targeting LILRB1 (Leukocyte Immunoglobulin-Like Receptor B1), also known as ILT2 or CD85j. LILRB1 is an inhibitory receptor expressed on myeloid cells and certain lymphocyte subsets that recognizes classical and non-classical MHC class I molecules. Upon ligand binding, LILRB1 transmits inhibitory signals through immunoreceptor tyrosine-based inhibition motifs (ITIMs), suppressing immune cell activation and promoting immune tolerance. This receptor plays a critical role in tumor immune evasion, as cancer cells exploit LILRB1 signaling to dampen anti-tumor immunity. Elevated LILRB1 expression has been associated with various malignancies and contributes to the immunosuppressive tumor microenvironment.
AGEN-1571 is a clinical-stage therapeutic antibody designed to block LILRB1-mediated immune suppression, thereby enhancing anti-tumor immune responses. This biosimilar provides researchers with a valuable tool for investigating LILRB1 biology, studying immune checkpoint mechanisms, and exploring therapeutic strategies in oncology and immunology research. It enables the examination of LILRB1's role in immune regulation and its potential as a target for cancer immunotherapy.
There are currently no reviews for this product.